Effect of Size on the Biodistribution and Blood Clearance of Etoposide-Loaded PLGA Nanoparticles

References

1. 1.↵
   1. Henwood J. M.,
   2. Brogden R. N.

   Etoposide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer. Drugs 1990, 39 (3),438– 490

   OpenUrlPubMedWeb of Science
2. 2.↵
   1. Dong Y.,
   2. Feng S. S.

   Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 2004, 25 (14),2843–2849

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Davis S. S.

   Biomedical applications of nanotechnology—implications for drug targeting and gene therapy. Trends Biotechnol. 1997, 15 (6), 217– 224

   OpenUrlCrossRefPubMedWeb of Science
4. 4.↵
   1. Yadav K. S.,
   2. Sawant K. K.

   Formulation optimization of etoposide-loaded PLGA nanoparticles by double factorial design and their evaluation. Curr. Drug Del. 2010, 7 (1),51–64

   OpenUrl
5. 5.↵
   1. Illum L.,
   2. Davis S. S.,
   3. Wilson C. G.,
   4. Thomas N. W.,
   5. Frier M.,
   6. Hardy J. G.

   Blood clearance and organ disposition of intravenously administered colloidal particles: effect of particle size, nature and shape. Int. J. Pharm. 1982, 12 (2–3)135–146

   OpenUrlCrossRef
6. 6.↵
   1. Moghimi S. M.,
   2. Hunter A. C.,
   3. Murray J. C.

   Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53 (2),283–318

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Sonavane G.,
   2. Tomoda K.,
   3. Makino K.

   Biodistribution of colloidal gold nanoparticles after intravenous administration: Effect of particle size. Colloids Surf., B 2008, 66 (2),274–280

   OpenUrl
8. 8.↵
   1. Banerjee S.,
   2. Pillai M. R.,
   3. Ramamoorthy N.

   Evolution of Tc-99m in diagnostic radiopharmaceuticals. Semin. Nucl. Med. 2001, 31 (4),260–277

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Sampson C. B.

   1. Theobald A. E.

   “Quality control of radiopharmaceuticals.” In Textbook of Radiopharmacy: Theory and Practice; Sampson C. B. Ed., New York: Gordan and Breach, 1990; pp 127–129
10. 10.↵
    1. Banerjee T.,
    2. Singh A. K.,
    3. Sharma R. K.,
    4. Maitra A. N.

    Labeling efficiency and biodistribution of Technetium-99m labeled nanoparticles: interference by colloidal tin oxide particles. Int. J. Pharm. 2005, 289 (1–2),189–195

    OpenUrlPubMed
11. 11.↵
    1. Yadav K. S.,
    2. Chuttani K.,
    3. Mishra A. K.,
    4. Sawant K. K.

    Long circulating nanoparticles of etoposide using PLGA-MPEG and PLGA-pluronic block copolymers: characterization, drug release, blood-clearance, and biodistribution studies. Drug Dev. Res. 2010, 71 (4),228– 239

    OpenUrl
12. 12.↵
    1. Brigger I.,
    2. Dubernet C.,
    3. Couvreur P.

    Nanoparticles in cancer therapy and diagnosis. Adv. Drug Del. Rev. 2002, 54 (5),631– 651

    OpenUrlCrossRefPubMedWeb of Science
13. 13.↵
    1. Gaur U.,
    2. Sahoo S. K.,
    3. De T. K.,
    4. Maitra A. N.,
    5. Ghosh P. C.,
    6. Ghosh P. K.

    Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int. J. Pharm. 2000, 202 (1–2),1–10

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Olivier J. C.

    Drug transport to brain with targeted nanoparticles. NeuroRx 2005, 2 (1),108– 119

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Bazile D.,
    2. Prudhomme C.,
    3. Bassoullet M. T.,
    4. Marlard M.,
    5. Spenlehauer G.,
    6. Veillard M.

    Stealth Me.PEG-PLA nanoparticules avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 1995, 84 (4),493– 498

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Zhang S.,
    2. Li J.,
    3. Lykotrafitis G.,
    4. Bao G.,
    5. Suresh S.

    Size-dependent endocytosis of nanoparticles. Adv. Mater. 2009, 21 (4),419– 424

    OpenUrlPubMed